NeoGenomics joins Thermo Fisher's companion diagnostic center of excellence program with the launch of Oncomine Dx Target test [Seeking Alpha]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Seeking Alpha
NeoGenomics joins Thermo Fisher's companion diagnostic center of excellence program with the launch of Oncomine Dx Target testNeoGenomics (NASDAQ:NEO)signs an agreement with Thermo Fisher Scientific (NYSE:TMO) to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. NeoGenomics is one of the first laboratories to offer the newly FDA-approved Oncomine Dx Target Test for Non-Small Cell Lung Cancer (NSCLC). This methodology allows rapid analysis of samples compared to previously approved testing approaches.NeoGenomics' Pharma Services Division supported the analytical validation of the Oncomine Dx Target Test for submission to the FDA. The test evaluates 23 genes associated with NSCLC.Now read:Co-Diagnostics (CODX) Presents At Lytham Partners Virtual Investor Conference - Slideshow »
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics, Inc. (NASDAQ: NEO) had its price target lowered by analysts at TD Cowen from $21.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- NeoGenomics, Inc. (NASDAQ: NEO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $18.00 price target on the stock.MarketBeat
- NeoGenomics, Inc. (NASDAQ: NEO) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $26.00 price target on the stock.MarketBeat
- NeoGenomics, Inc. (NASDAQ: NEO) had its price target lowered by analysts at Needham & Company LLC from $24.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
- NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 4/30/24 - Beat
NEO
Sec Filings
- 4/30/24 - Form 10-Q
- 4/30/24 - Form 8-K
- 4/18/24 - Form 8-K
- NEO's page on the SEC website